secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001104659-25-111931
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q3 net loss $102.2M; Type A FDA meeting positive for apitegromab BLA resubmission in 2026
--------------------------------------------------------------------------------

- Net loss $102.2M (EPS -$0.90) vs $64.5M (EPS -$0.66) YoY; no revenue.
- Cash $369.6M; plus ~$60M from warrants expiring Dec 31, 2025, expected to fund into 2027.
- Type A meeting with FDA completed Nov 12; BLA resubmission and U.S. launch for apitegromab in SMA anticipated in 2026.
- Second U.S. fill-finish facility secured; commercial capacity reserved starting Q1 2026.
- FDA cleared IND for SRK-439; dosing in healthy volunteers to begin Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/0001104659-25-111931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer